Daria M Keller, Natasha Ahmed, Hamza Tariq, Malsha Walgamage, Thilini Walgamage, Azad Mohammed, Jadzia Tin-Tsen Chou, Marta Kałużna-Oleksy, Maciej Lesiak, Ewa Straburzyńska-Migaj. J Clin Med 2022
Times Cited: 4
Times Cited: 4
Times Cited
Times Co-cited
Similarity
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.
Subodh Verma, John J V McMurray. Diabetologia 2018
Subodh Verma, John J V McMurray. Diabetologia 2018
50
Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.
W Timothy Garvey, Luc Van Gaal, Lawrence A Leiter, Ujjwala Vijapurkar, James List, Robert Cuddihy, Jimmy Ren, Michael J Davies. Metabolism 2018
W Timothy Garvey, Luc Van Gaal, Lawrence A Leiter, Ujjwala Vijapurkar, James List, Robert Cuddihy, Jimmy Ren, Michael J Davies. Metabolism 2018
50
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Hiddo J L Heerspink, Bruce A Perkins, David H Fitchett, Mansoor Husain, David Z I Cherney. Circulation 2016
Hiddo J L Heerspink, Bruce A Perkins, David H Fitchett, Mansoor Husain, David Z I Cherney. Circulation 2016
50
A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.
Motoaki Sano. J Cardiol 2018
Motoaki Sano. J Cardiol 2018
25
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
25
Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study.
Eu Jeong Ku, Dong-Hwa Lee, Hyun Jeong Jeon, Tae Keun Oh. Diabetes Res Clin Pract 2021
Eu Jeong Ku, Dong-Hwa Lee, Hyun Jeong Jeon, Tae Keun Oh. Diabetes Res Clin Pract 2021
25
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetologia 2018
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetologia 2018
25
Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease.
L Zanoli, A Granata, P Lentini, S Rastelli, P Fatuzzo, F Rapisarda, P Castellino. ScientificWorldJournal 2015
L Zanoli, A Granata, P Lentini, S Rastelli, P Fatuzzo, F Rapisarda, P Castellino. ScientificWorldJournal 2015
25
Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.
Jian Li, Yanping Gong, Chunlin Li, Yanhui Lu, Yu Liu, Yinghong Shao. Medicine (Baltimore) 2017
Jian Li, Yanping Gong, Chunlin Li, Yanhui Lu, Yu Liu, Yinghong Shao. Medicine (Baltimore) 2017
25
Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling.
Muthiah Vaduganathan, Vasanth Sathiyakumar, Avinainder Singh, Cian P McCarthy, Arman Qamar, James L Januzzi, Benjamin M Scirica, Javed Butler, Christopher P Cannon, Deepak L Bhatt. J Am Coll Cardiol 2018
Muthiah Vaduganathan, Vasanth Sathiyakumar, Avinainder Singh, Cian P McCarthy, Arman Qamar, James L Januzzi, Benjamin M Scirica, Javed Butler, Christopher P Cannon, Deepak L Bhatt. J Am Coll Cardiol 2018
25
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Soo Lim, Robert H Eckel, Kwang Kon Koh. Atherosclerosis 2018
Soo Lim, Robert H Eckel, Kwang Kon Koh. Atherosclerosis 2018
25
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials.
David M Williams, Asif Nawaz, Marc Evans. Diabetes Ther 2021
David M Williams, Asif Nawaz, Marc Evans. Diabetes Ther 2021
25
Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations.
David M Williams, Hannah Jones, Jeffrey W Stephens. Diabetes Metab Syndr Obes 2022
David M Williams, Hannah Jones, Jeffrey W Stephens. Diabetes Metab Syndr Obes 2022
25
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
25
Mortality attributable to type 2 diabetes mellitus in Latin America and the Caribbean: a comparative risk assessment analysis.
Wilmer Cristobal Guzman-Vilca, Rodrigo M Carrillo-Larco. BMJ Open Diabetes Res Care 2022
Wilmer Cristobal Guzman-Vilca, Rodrigo M Carrillo-Larco. BMJ Open Diabetes Res Care 2022
100
Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors.
Mei Qiu, Liang-Liang Ding, Miao Zhang, Hai-Rong Zhou. Diab Vasc Dis Res 2021
Mei Qiu, Liang-Liang Ding, Miao Zhang, Hai-Rong Zhou. Diab Vasc Dis Res 2021
25
Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels.
C D Sjöström, M Hashemi, J Sugg, A Ptaszynska, E Johnsson. Diabetes Obes Metab 2015
C D Sjöström, M Hashemi, J Sugg, A Ptaszynska, E Johnsson. Diabetes Obes Metab 2015
25
Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results.
Sean Kang, Subodh Verma, Ali Fatehi Hassanabad, Guoqi Teng, Darrell D Belke, Jameson A Dundas, David G Guzzardi, Daniyil A Svystonyuk, Simranjit S Pattar, Daniel S J Park,[...]. Can J Cardiol 2020
Sean Kang, Subodh Verma, Ali Fatehi Hassanabad, Guoqi Teng, Darrell D Belke, Jameson A Dundas, David G Guzzardi, Daniyil A Svystonyuk, Simranjit S Pattar, Daniel S J Park,[...]. Can J Cardiol 2020
25
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Ralph A DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J Woerle, Uli C Broedl. Diabetes Care 2015
Ralph A DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J Woerle, Uli C Broedl. Diabetes Care 2015
25
Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin.
Ai-Yu Yang, Hung-Chun Chen. Int J Clin Pharm 2021
Ai-Yu Yang, Hung-Chun Chen. Int J Clin Pharm 2021
50
Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review.
Soghra Rabizadeh, Manouchehr Nakhjavani, Alireza Esteghamati. Int J Endocrinol Metab 2019
Soghra Rabizadeh, Manouchehr Nakhjavani, Alireza Esteghamati. Int J Endocrinol Metab 2019
25
Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells.
A Solini, G Sebastiani, L Nigi, E Santini, C Rossi, F Dotta. Diabetes Metab 2017
A Solini, G Sebastiani, L Nigi, E Santini, C Rossi, F Dotta. Diabetes Metab 2017
25
Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes.
Yun Kyung Cho, Jiwoo Lee, Yu Mi Kang, Jee Hee Yoo, Joong-Yeol Park, Chang Hee Jung, Woo Je Lee. PLoS One 2019
Yun Kyung Cho, Jiwoo Lee, Yu Mi Kang, Jee Hee Yoo, Joong-Yeol Park, Chang Hee Jung, Woo Je Lee. PLoS One 2019
25
Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease.
Shih-Chieh Shao, Kai-Cheng Chang, Swu-Jane Lin, Shang-Hung Chang, Ming-Jui Hung, Yuk-Ying Chan, Edward Chia-Cheng Lai. Cardiovasc Diabetol 2021
Shih-Chieh Shao, Kai-Cheng Chang, Swu-Jane Lin, Shang-Hung Chang, Ming-Jui Hung, Yuk-Ying Chan, Edward Chia-Cheng Lai. Cardiovasc Diabetol 2021
25
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021.
. Diabetes Care 2021
. Diabetes Care 2021
25
Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Tamara Y Milder, Sophie L Stocker, Christina Abdel Shaheed, Lucy McGrath-Cadell, Dorit Samocha-Bonet, Jerry R Greenfield, Richard O Day. J Clin Med 2019
Tamara Y Milder, Sophie L Stocker, Christina Abdel Shaheed, Lucy McGrath-Cadell, Dorit Samocha-Bonet, Jerry R Greenfield, Richard O Day. J Clin Med 2019
25
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.
Christian W Mende. Adv Ther 2022
Christian W Mende. Adv Ther 2022
25
Exploring New Drug Targets for Type 2 Diabetes: Success, Challenges and Opportunities.
Abhinav Kanwal, Navjot Kanwar, Sanjay Bharati, Prateek Srivastava, Shailendra P Singh, Salomon Amar. Biomedicines 2022
Abhinav Kanwal, Navjot Kanwar, Sanjay Bharati, Prateek Srivastava, Shailendra P Singh, Salomon Amar. Biomedicines 2022
50
Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities.
Emily Brown, John P H Wilding, Thomas M Barber, Uazman Alam, Daniel J Cuthbertson. Obes Rev 2019
Emily Brown, John P H Wilding, Thomas M Barber, Uazman Alam, Daniel J Cuthbertson. Obes Rev 2019
25
Changes in type 2 diabetes incidence and mortality associated with introduction of HbA1c as diagnostic option: A Danish 24-year population-based study.
Jakob S Knudsen, Signe S Knudsen, Adam Hulman, Daniel R Witte, Edward W Gregg, Torsten Lauritzen, Lars Pedersen, Henrik T Sørensen, Reimar W Thomsen. Lancet Reg Health Eur 2022
Jakob S Knudsen, Signe S Knudsen, Adam Hulman, Daniel R Witte, Edward W Gregg, Torsten Lauritzen, Lars Pedersen, Henrik T Sørensen, Reimar W Thomsen. Lancet Reg Health Eur 2022
25
Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
Arnaud D Kaze, Min Zhuo, Seoyoung C Kim, Elisabetta Patorno, Julie M Paik. Cardiovasc Diabetol 2022
Arnaud D Kaze, Min Zhuo, Seoyoung C Kim, Elisabetta Patorno, Julie M Paik. Cardiovasc Diabetol 2022
25
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.
Qiming Tan, Seun E Akindehin, Camila E Orsso, Richelle C Waldner, Richard D DiMarchi, Timo D Müller, Andrea M Haqq. Front Endocrinol (Lausanne) 2022
Qiming Tan, Seun E Akindehin, Camila E Orsso, Richelle C Waldner, Richard D DiMarchi, Timo D Müller, Andrea M Haqq. Front Endocrinol (Lausanne) 2022
25
Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus.
Maria Mirabelli, Eusebio Chiefari, Patrizia Caroleo, Raffaella Vero, Francesco Saverio Brunetti, Domenica Maria Corigliano, Biagio Arcidiacono, Daniela Patrizia Foti, Luigi Puccio, Antonio Brunetti. J Diabetes Res 2019
Maria Mirabelli, Eusebio Chiefari, Patrizia Caroleo, Raffaella Vero, Francesco Saverio Brunetti, Domenica Maria Corigliano, Biagio Arcidiacono, Daniela Patrizia Foti, Luigi Puccio, Antonio Brunetti. J Diabetes Res 2019
25
Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019.
Saeid Safiri, Nahid Karamzad, Jay S Kaufman, Arielle Wilder Bell, Seyed Aria Nejadghaderi, Mark J M Sullman, Maziar Moradi-Lakeh, Gary Collins, Ali-Asghar Kolahi. Front Endocrinol (Lausanne) 2022
Saeid Safiri, Nahid Karamzad, Jay S Kaufman, Arielle Wilder Bell, Seyed Aria Nejadghaderi, Mark J M Sullman, Maziar Moradi-Lakeh, Gary Collins, Ali-Asghar Kolahi. Front Endocrinol (Lausanne) 2022
25
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
25
Harms and benefits of sodium-glucose co-transporter 2 inhibitors.
Thomas Chesterman, Tilenka Rj Thynne. Aust Prescr 2020
Thomas Chesterman, Tilenka Rj Thynne. Aust Prescr 2020
25
Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.
Kevin Yau, Atit Dharia, Ibrahim Alrowiyti, David Z I Cherney. Kidney Int Rep 2022
Kevin Yau, Atit Dharia, Ibrahim Alrowiyti, David Z I Cherney. Kidney Int Rep 2022
25
New Diabetic Medication Sodium-Glucose Cotransporter-2 Inhibitors Can Induce Euglycemic Ketoacidosis and Mimic Surgical Diseases: A Case Report and Review of Literature.
Antonia-Therese Kietaibl, Peter Fasching, Karl Glaser, Alexander H Petter-Puchner. Front Surg 2022
Antonia-Therese Kietaibl, Peter Fasching, Karl Glaser, Alexander H Petter-Puchner. Front Surg 2022
33
Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts.
Tsung-Ming Lee, Nen-Chung Chang, Shinn-Zong Lin. Free Radic Biol Med 2017
Tsung-Ming Lee, Nen-Chung Chang, Shinn-Zong Lin. Free Radic Biol Med 2017
25
Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
Eu Jeong Ku, Dong-Hwa Lee, Hyun Jeong Jeon, Tae Keun Oh. Diabetes Res Clin Pract 2019
Eu Jeong Ku, Dong-Hwa Lee, Hyun Jeong Jeon, Tae Keun Oh. Diabetes Res Clin Pract 2019
25
Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis.
Siddhartha Dutta, Tarun Kumar, Surjit Singh, Sneha Ambwani, Jaykaran Charan, Shoban B Varthya. J Family Med Prim Care 2022
Siddhartha Dutta, Tarun Kumar, Surjit Singh, Sneha Ambwani, Jaykaran Charan, Shoban B Varthya. J Family Med Prim Care 2022
33
25
Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Faiez Zannad. JAMA Cardiol 2017
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Faiez Zannad. JAMA Cardiol 2017
25
An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.
Daniel S Hsia, Owen Grove, William T Cefalu. Curr Opin Endocrinol Diabetes Obes 2017
Daniel S Hsia, Owen Grove, William T Cefalu. Curr Opin Endocrinol Diabetes Obes 2017
25
SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.
Shiho Komatsu, Takashi Nomiyama, Tomohiro Numata, Takako Kawanami, Yuriko Hamaguchi, Chikayo Iwaya, Tsuyoshi Horikawa, Yuki Fujimura-Tanaka, Nobuya Hamanoue, Ryoko Motonaga,[...]. Endocr J 2020
Shiho Komatsu, Takashi Nomiyama, Tomohiro Numata, Takako Kawanami, Yuriko Hamaguchi, Chikayo Iwaya, Tsuyoshi Horikawa, Yuki Fujimura-Tanaka, Nobuya Hamanoue, Ryoko Motonaga,[...]. Endocr J 2020
25
Baicalein suppresses high glucose-induced inflammation and apoptosis in trophoblasts by targeting the miRNA-17-5p-Mfn1/2-NF-κB pathway.
Jie Li, Yang Wang, Tong Wu, Si Li, Ya-Nan Sun, Zhi-Hui Liu. Placenta 2022
Jie Li, Yang Wang, Tong Wu, Si Li, Ya-Nan Sun, Zhi-Hui Liu. Placenta 2022
33
Serological Phenotyping Analysis Uncovers a Unique Metabolomic Pattern Associated With Early Onset of Type 2 Diabetes Mellitus.
Linmin Zhu, Qianyang Huang, Xiao Li, Bo Jin, Yun Ding, C James Chou, Kuo-Jung Su, Yani Zhang, Xingguo Chen, Kuo Yuan Hwa,[...]. Front Mol Biosci 2022
Linmin Zhu, Qianyang Huang, Xiao Li, Bo Jin, Yun Ding, C James Chou, Kuo-Jung Su, Yani Zhang, Xingguo Chen, Kuo Yuan Hwa,[...]. Front Mol Biosci 2022
50
Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank.
Nicholas J Thomas, Samuel E Jones, Michael N Weedon, Beverley M Shields, Richard A Oram, Andrew T Hattersley. Lancet Diabetes Endocrinol 2018
Nicholas J Thomas, Samuel E Jones, Michael N Weedon, Beverley M Shields, Richard A Oram, Andrew T Hattersley. Lancet Diabetes Endocrinol 2018
25
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.